title: [Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?].
abstract: OBJECTIVE
  The indication for medical venous thrombosis prophylaxis in ambulatory cancer patients is still under discussion. To provide more data on this topic we conducted an analysis in ambulatory patients with advanced pancreatic adenocarcinoma, reflecting a patient cohort at high risk of symptomatic venous thromboembolism (sVTE).
  
  
  METHODS
  Data from 312 consecutively recruited patients of the CONKO-004 trial were analysed according to predefined parameters and additionally with respect to established scores. To focus on patients with highest risk of sVTE unvaried and multivariate analyses were conducted.
  
  
  RESULTS
  The global analyses had educed a number needed to treat (NNT) by medical thrombosis prophylaxis of 12 patients to prevent one sVTE. The modified score model did not provide further clinical benefit. However, the regression model can identify single parameters with a trend to higher risk of sVTE or higher risk of severe bleeding. Most of the parameters do not have enough power to be significant, but they can support clinical decisions.
  
  
  CONCLUSIONS
  These data suggest that medical thrombosis prophylaxis should be performed in patients with advanced pancreatic cancer at least for the initial 3 months of first line chemotherapy.
authors.affiliation: Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité - Universitätsmedizin Berlin.
authors.forename: U
authors.initials: U
authors.lastname: Pelzer
authors.forename: M
authors.initials: M
authors.lastname: Sinn
authors.forename: J
authors.initials: J
authors.lastname: Stieler
authors.forename: H
authors.initials: H
authors.lastname: Riess
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D000553:Ambulatory Care; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D017985:Dalteparin / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D017984:Enoxaparin / Q000008:administration & dosage* / Q000009:adverse effects; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced; D006801:Humans; D007279:Injections, Subcutaneous; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D015996:Survival Rate; D054556:Venous Thromboembolism / Q000401:mortality / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D017985:Dalteparin